Spending Reductions With the Medicare Shared Savings Program, Extended Caffeine Use in Preterm Infants, Survival Trends for Periviable Infants, and more
·8 min
The episode begins with hosts Dr. Kirsten Bibbins-Domingo and Dr. Preeti Malani introducing the weekly JAMA Editors' Summary. They first discuss a study by Dr. Bond and colleagues using nearly a decade of Medicare data to analyze spending reductions in Accountable Care Organizations within the Medicare Shared Savings Program, with an editorial by Dr. Owaiyagode and Kola providing context. Next, they highlight research from the Pediatric Academic Society meeting, including a randomized trial by Dr. Carlo and colleagues where extended caffeine treatment did not shorten hospitalization for moderately preterm infants. Another study by Dr. Boghossian and colleagues found increased active treatment and survival for infants born at 22 weeks gestation, while Dr. Chua and colleagues reported on Flovent withdrawal leading to inhaled steroid therapy discontinuation in children. Shifting to adult medicine, Dr. Kim and colleagues' research letter reveals disparities in prescribing semaglutide and terzepatide based on race, ethnicity, social vulnerability, and urbanicity. Opinion content includes a perspective by Dr. Zhang and colleagues on AI regulation in Chinese hospitals, another by Dr. Brennan and Professor Cole on anti-discrimination law, and a JAMA Climate Change article on metered dose inhalers' greenhouse gas emissions. Viewpoints cover heavy media use in children, FDA layoffs, institutional review board changes, sugar-sweetened beverage taxes, and abolishing daylight savings time. The episode also mentions the SPIRIT 2025 statement updates for clinical trial protocols, a clinical review on non-cystic fibrosis bronchiectasis, an insights article on Factor V Leiden, a patient page on cardiac arrest in young adults, and medical news on synthetic food dyes and nutritional education gaps. It concludes with production credits and resource links.
